Product Licensing

Crucell, partner, announce PER.C6 licensing agreement

Published in Bioterrorism Week, October 11th, 2004

Vaxin, Inc., has entered into a license agreement with Dutch biotechnology company Crucell, NV, (CRXL).

This nonexclusive license agreement allows Vaxin to use Crucell's PER.C6 cell line for the development, manufacture, and commercialization of its recombinant adenoviral vaccines against certain respiratory viruses.

Under the terms of the agreement, Crucell will receive an upfront payment, annual maintenance fees, and royalties on future sales. Further financial details were not disclosed.

"The PER.C6 technology is a well-established cell line that is utilized by leading pharmaceutical companies around the world," stated Frank...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Bioterrorism Week

Source: Bioterrorism Week (2004-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry